Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients-Reference-Cited by-同舟云学术

Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients

Published:2019-03-21 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Aoki Shuichi, ,Motoi Fuyuhiko^ORCID,Murakami Yoshiaki,Sho Masayuki,Satoi Sohei,Honda Goro,Uemura Kenichiro,Okada Ken-ichi,Matsumoto Ippei,Nagai Minako,Yanagimoto Hiroaki,Kurata Masanao,Fukumoto Takumi,Mizuma Masamichi,Yamaue Hiroki,Unno Michiaki

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5460-4.pdf

Reference35 articles.

1. Nakao A, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, Kodera Y, Inoue S, Takeda S. Oncological problems in pancreatic cancer surgery. World J Gastroenterol. 2006;12(28):4466–72.

2. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21(2):195–200.

3. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, Weitz J. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882–93.